13,567 bottles of chlorthalidone blood pressure pills are recalled after failing dissolution tests

Inventia Healthcare Limited is recalling 13,567 bottles of chlorthalidone tablets, a blood pressure and fluid-retention drug, because the product failed dissolution specifications. The 25 mg tablets were sold in 100-count bottles from a single lot, RISA24002, with an April 2027 expiration date, and were distributed nationwide. The Food and Drug Administration classified the action as Class II on September 17, 2026, two weeks after the company began the recall.

Dissolution failures rarely make headlines, in part because nothing about the pill looks wrong. The defect is one of performance: whether a tablet releases its active ingredient into the body at the rate its approved specification requires. For a medicine taken daily to hold blood pressure steady, that gap can matter even when the bottle seems normal.

The lot, the count and the paperwork

Local reporting by News4JAX lists the affected product as Chlorthalidone Tablets, USP, 25 mg, under National Drug Code 64980-599-01, with recall number D-0852-2026. Inventia, an India-based manufacturer, voluntarily initiated the recall on September 3. Becker’s Hospital Review reports the same figures, 13,567 bottles and a status of ongoing, and quotes the reason as the product having “failed dissolution specifications.”

Recall classifications are published in the FDA’s Enforcement Report, and the agency’s Enforcement Report search page is where individual entries are looked up by product or recall number. The entry itself could not be retrieved for this article, so the figures here rest on the two news reports and are consistent between them. The public notices name a lot and an NDC but no pharmacy chain, so patients have to check the label on their own bottle instead of waiting to be told which stores are involved.

What failing dissolution means

A tablet has to break apart and dissolve before its drug can be absorbed. FDA guidance on dissolution testing says it exists to “provide general recommendations for dissolution testing” and to help set specifications tied to how a drug behaves in the body, and that testing also helps “ensure continuous drug product quality and performance” after manufacturing changes. In practice, a lot fails when a sample does not release enough drug within the time and amount set in its specification. For a daily diuretic, release that is too slow or too incomplete could mean less of the drug is working at a given hour than the label implies, though none of the published accounts says any patient was harmed.

The FDA guidance dates from August 1997, so the test is long established rather than novel. The news reports do not say how far the failing lot missed its target or which test point it failed, and Inventia has not published those details in any source that has been reviewed here. What is on record is the fact of the failure, not its size.

Why the FDA called it Class II

The FDA’s recall definitions describe a Class II recall as “a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.” The most serious tier is reserved for a “reasonable probability” of serious harm or death, and the mildest for products “not likely to cause adverse health consequences.” The middle tier fits a tablet that may under-deliver its dose: any harm would come from blood pressure being less well controlled, not from a contaminant.

The sequence of dates shows how the process runs. Inventia started the recall on its own on September 3; the FDA assigned the Class II rating on September 17; local outlets reported it on September 28. The FDA’s definitions page notes that recalls “may be initiated by the company itself, requested by the FDA, or mandated by FDA order,” and the reports describe this one as voluntary, so the classification is the agency’s assessment of risk, not a new order to the company.

Chlorthalidone belongs to the diuretic family, the so-called water pills. MedlinePlus explains that it “causes the kidneys to get rid of unneeded water and salt from the body into the urine,” and that it “controls high blood pressure but does not cure it.” The same page tells patients to keep taking the drug even when they feel well, which is why a possibly weak lot deserves attention even when no symptoms appear, since high blood pressure often produces none.

What patients are told to do

News4JAX reports that patients should check whether their medication matches the affected lot and then contact a pharmacist or physician, and that health care providers can report adverse events to the FDA’s MedWatch program at 1-800-FDA-1088. Neither the recall notices nor the reports call for anyone to stop taking the drug without medical advice, and MedlinePlus warns that stopping blood pressure treatment can let blood pressure rise again.

A match on the lot number and NDC on the label is the deciding test, since the recall covers one lot only. Whether Inventia will widen the recall to other lots is not addressed in any of the published accounts.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview